Concepedia

Andrew J. Wagner

AJ

Statistics

Publications

135

Citations

12.5K

H-Index

60

Active since

1990

Affiliations

Dana-Farber Cancer Institute(Current)

Harvard University

Memorial Sloan Kettering Cancer Center

Brigham and Women's Hospital

Cornell University

Andrew J. Wagner is an author at Dana-Farber Cancer Institute specializing in medicine, oncology, and pharmacology.

ORCID

Publications per year

1990–2024

135

Publications

135

The PI 3-kinase/Akt signaling pathway delivers an anti-apoptotic signal.

Scott Kennedy, Andrew J. Wagner, Suzanne D. Conzen et al. · Genes & Development · 1997 · 1.1K citations · Full text

, , +16

Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor

William D. Tap, Zev A. Wainberg, Stephen P. Anthony et al. · New England Journal of Medicine · 2015 · 582 citations

, , +15

Myc-mediated apoptosis requires wild-type p53 in a manner independent of cell cycle arrest and the ability of p53 to induce p21waf1/cip1.

Andrew J. Wagner, John M. Kokontis, Nissim Hay · Genes & Development · 1994 · 536 citations · Full text

, , +17

Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial

William D. Tap, Hans Gelderblom, Emanuela Palmerini et al. · The Lancet · 2019 · 474 citations · Full text

, , +5

Clinical Activity of mTOR Inhibition With Sirolimus in Malignant Perivascular Epithelioid Cell Tumors: Targeting the Pathogenic Activation of mTORC1 in Tumors

Andrew J. Wagner, Izabela Malinowska-Kołodziej, Jeffrey A. Morgan et al. · Journal of Clinical Oncology · 2010 · 391 citations

, , +15

1–5 of 135